Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ISIS 757456
Ionis AGT-LRx · 4 trials · 3 indications
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug.
| Arm | Type | Description |
|---|---|---|
| IONIS-AGT-LRx | EXPERIMENTAL | IONIS-AGT-LRX by subcutaneous injection once-weekly |
| Placebo | PLACEBO_COMPARATOR | Matching placebo by subcutaneous injection once-weekly |
| Pooled Placebo | PLACEBO_COMPARATOR | Participants received ISIS 757456 matching placebo subcutaneously once weekly for 12 weeks. |
| IONIS-AGT-LRx 80 mg | EXPERIMENTAL | Participants received ISIS 757456 80 milligrams (mg), subcutaneous (SC) injection, once weekly for 12 weeks. |
| IONIS-AGT-LRx 120 mg | EXPERIMENTAL | Participants received ISIS 757456 120 mg, SC injection, once weekly for 12 weeks. |
| ISIS 757456 | EXPERIMENTAL | Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3. |
| ISIS 757456 80 mg | EXPERIMENTAL | ISIS 757456 80 mg injected SC once weekly for up to 6 weeks and an additional loading dose of 80 mg on Day 3. |
| Name | Type | Description |
|---|---|---|
| IONIS-AGT-LRx | DRUG | Multiple doses of IONIS-AGT-LRx will be administered by SC injection. |
| Placebo | DRUG | IONIS-AGT-LRx-matching placebo will be administered by SC injection. |
| ISIS 757456 | DRUG | ISIS 757456 administered as SC injection. |
Inclusion Criteria: 1. Females must be non-pregnant and non-lactating and of non- childbearing potential. 2. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), she must be willing to use a highly effective contraceptive...
Ionis AGT-LRx is an investigational small molecule developed by Ionis Pharmaceuticals, Inc. (ticker: IONS) for cardiovascular conditions. It has been studied in Phase 2 clinical trials for chronic heart failure with reduced ejection fraction and for hypertension in patients with uncontrolled blood pressure. It is not an approved therapy.
Ionis AGT-LRx has been evaluated for two cardiovascular indications: chronic heart failure with reduced ejection fraction and hypertension in patients with uncontrolled blood pressure. Both uses were studied in Phase 2 clinical trials that have been completed. The drug remains investigational and is not approved for any indication.
Ionis AGT-LRx is developed by Ionis Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker IONS. Ionis is the sponsor of the Phase 2 clinical program evaluating the drug in chronic heart failure with reduced ejection fraction and in hypertension with uncontrolled blood pressure.
Ionis AGT-LRx is in Phase 2 development. Two Phase 2 trials have been completed, one in chronic heart failure with reduced ejection fraction and one in hypertensive patients with uncontrolled blood pressure. The drug is investigational and has not been approved by the FDA for any indication.
Ionis AGT-LRx has been studied in two completed Phase 2 trials. NCT04836182 evaluated the drug in participants with chronic heart failure with reduced ejection fraction across the United States, Hungary, and Poland. NCT04714320 evaluated it in hypertensive participants with uncontrolled blood pressure in the United States and Canada.
Yes, Ionis AGT-LRx and IONIS-AGT-LRx refer to the same investigational drug. IONIS-AGT-LRx is the alternate name used in trial registrations and scientific literature, while Ionis AGT-LRx is the shorter form. Both names identify the same Phase 2 small molecule from Ionis Pharmaceuticals.